| Literature DB >> 25709475 |
Yufei Zhao1, Yanming Du1, Shengnan Zhao1, Zhanjun Guo1.
Abstract
OBJECTIVE: MicroRNA (miRNA)-related single-nucleotide polymorphisms (miR-SNPs) in miRNA processing machinery genes can affect cancer risk, treatment efficacy, and patient prognosis. We genotyped 6 miR-SNPs of miRNA processing machinery genes including XPO5 (rs11077), RAN (rs14035), Dicer (rs3742330), TNRC6B (rs9623117), GEMIN3 (rs197412), and GEMIN4 (rs2740348) in a case-control study to evaluate their impact on colorectal cancer (CRC) risk.Entities:
Keywords: CRC; Dicer; GEMIN3; miR-SNP
Year: 2015 PMID: 25709475 PMCID: PMC4334349 DOI: 10.2147/OTT.S78647
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Primers and probes used for genotyping of miR-SNPs
| Gene | rs NCBI | Primer sequence | Probe sequence |
|---|---|---|---|
| rs11077 (A/C) | F GAATCTGGTCACCTGATGGGA | S1 GTACCTCCAAGGACCAGGGCTGGGA | |
| rs14035 (C/T) | F GCACTTGCTCAAAATCTGTGA | S1 TTTTAGTAATCATGTTTTAATGTAGAACC | |
| rs3742330 (A/G) | F AAAGGTATCAAGGTCTCAGTTTG | S1 TTTTTTTTTTCAATCTTGTGTAAAGGGATTAGA | |
| rs9623117 (C/T) | F TTTCTGTCTCCTCCTATCCAT | S1 TCTCCCTGTTACTCTTAAGTAGTGC | |
| rs197412 (T/C) | F TAGAGAAACCTGTGGAAATCA | S1 TTTTATGGTTTTGTGAGAAATAAAGTTAC | |
| rs2740348 (G/C) | F TTGCCTCTGAGAAGAAGTGG | S1 TTTTTTTTGGGAGTAACAGGGCCCTCTTCCGAC |
Abbreviation: miR-SNPs, microRNA-related single-nucleotide polymorphisms.
Association of clinical characteristics with cancer risk in CRC patients
| CRC (n=163) | Control (n=142) | ||
|---|---|---|---|
| Age (years) | |||
| ≤60 | 79 | 66 | |
| >60 | 84 | 76 | 0.729 |
| Sex | |||
| Male | 93 | 93 | |
| Female | 70 | 49 | 0.132 |
| Smoking | |||
| Yes | 32 | 36 | |
| No | 131 | 106 | 0.231 |
| Obesity | |||
| Yes | 12 | 18 | |
| No | 151 | 124 | 0.120 |
| Alcohol consumption | |||
| Yes | 27 | 30 | |
| No | 136 | 112 | 0.308 |
| Tumor stage, TNM | |||
| I | 9 | ||
| II | 82 | ||
| III | 53 | ||
| IV | 19 | ||
Abbreviation: CRC, colorectal cancer.
Associations of the six SNPs with colorectal cancer risk
| Gene | SNP | Genotype | Number (%) of patients with each genotype
| Odds ratio | 95% CI | ||
|---|---|---|---|---|---|---|---|
| Case | Control | ||||||
| rs11077 | AA | 143 (12.3) | 123 (86.6) | 1.10 | 0.56–2.16 | 0.772 | |
| AC + CC | 20 (87.7) | 19 (13.4) | |||||
| rs14035 | CC | 113 (69.3) | 107 (75.4) | 0.74 | 0.45–1.23 | 0.242 | |
| CT + TT | 50 (30.7) | 35 (24.6) | |||||
| rs3742330 | AA | 92 (56.4) | 54 (38.0) | 2.11 | 1.33–3.34 | 0.001 | |
| AG + GG | 71 (43.6) | 88 (62.0) | |||||
| rs9623117 | TT | 149 (91.4) | 128 (90.1) | 1.16 | 0.54–2.53 | 0.702 | |
| CT + CC | 14 (8.6) | 14 (9.9) | |||||
| rs197412 | TT | 90 (55.2) | 60 (42.3) | 1.69 | 1.07–2.65 | 0.024 | |
| CT + CC | 73 (44.8) | 82 (57.7) | |||||
| rs2740348 | GG | 128 (78.5) | 114 (80.3) | 0.89 | 0.51–1.57 | 0.706 | |
| GC + CC | 35 (21.5) | 28 (19.7) | |||||
Abbreviations: CI, confidence interval; SNP, single-nucleotide polymorphism.